There are independent researchers who are contracted to do the research, but it is from the company. But it is transparent; the regulator sees all the data, good or bad, with it. So that's not an issue.
We are doing additional trials, and again, to be clear in terms of when we were talking before about what was planned, that has not changed. Nothing has been short-cut. But what we found is that after one dose there was good immunity. The six weeks would be required for two doses and the results of two doses before you'd know.
In Canada we have said, and I've been saying from the beginning, that we were working to have it available as soon as possible in terms of safe and effective vaccine, confident about the beginning of November. Nothing was shorted. The only additional thing the regulator might look for is immunity data following the second dose, etc., which would not change the decision about when to immunize.